Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, et al. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K beta/delta in relapsed refractory B cell lymphoma. Leuk Lymphoma 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957874.
PMID: 34365878